Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07403981 | Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients | recruiting | N/A | 60 | Stanford UniversityOTHER | 1 | Sep 8, 2026 |
| clinicaltrials |
| NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | not yet recruiting | Phase 2 | 51 | Zhejiang UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07795801 | Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors | not yet recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807800 | A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 1 / Phase 2 | 88 | D. E. Shaw Research, LLCINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | not yet recruiting | Phase 2 | 100 | Solstice Oncology, Inc.INDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01239082 | Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)(CONFIRM) | active not recruiting | N/A | 50,126 | VA Office of Research and DevelopmentFED | 2 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06333392 | Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | recruiting | N/A | 1,070 | Vestre Viken Hospital TrustOTHER | 2 | Sep 4, 2026 | clinicaltrials |
| NCT06787105 | Fruquintinib in Patients With Metastatic Colorectal Cancer(FRUQUENT) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07416552 | A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 | 180 | Hoffmann-La RocheINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07661641 | A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | recruiting | Phase 1 | 115 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 220 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04967183 | Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs. | active not recruiting | N/A | 3,788 | Fundacin Biomedica Galicia SurOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801352 | CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802197 | Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer(PRELUDE) | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04749108 | Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma(GRECCAR14) | recruiting | Phase 2 / Phase 3 | 1,075 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | active not recruiting | Phase 2 / Phase 3 | 168 | Compass TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05585814 | CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer(COBP) | active not recruiting | Phase 2 | 30 | Shanghai Changzheng HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06568016 | A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers | recruiting | N/A | 1,500 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07143487 | Family Communications After Genetic Testing | recruiting | N/A | 4,186 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | recruiting | N/A | 420 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766044 | A One-year Follow-up of Incisional Hernia Formation Between Device Assisted and Manual Laparotomy Closure | recruiting | N/A | 218 | Suturion ABINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07791758 | A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 369 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795528 | Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma(ADX-DRIVER-CRC) | recruiting | — | 392 | Ruijin HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05672316 | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer(FRUITION) | recruiting | Phase 2 | 120 | Criterium, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials